General

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Berenson A et al. Ann Hematol. 2016 Dec 8. [Epub ahead of print]. Practical Considerations in Managing Relapsed Multiple Myeloma. Agarwal A et al. Clin Lymphoma Myeloma Leuk. 2016 Nov 23. pii: S2152-2650(16)30873-4. doi: 10.1016/j.clml.2016.11.010. [Epub ahead of print]. Effects of Stress Appraisal on the Quality of Life of Adult Patients with Multiple Myeloma and Their Primary Family…

Details

Supportive treatments

Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study. Hansen PB et al. Support Care Cancer. 2016 Dec 13. [Epub ahead of print]. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M et al. Cochrane Database Syst Rev. 2016 Dec…

Details

Complications of myeloma and its treatments

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Jones JR et al. Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. Hinduja A et al. PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016. Bullous skin lesions in a patient…

Details

Current treatments

Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Skerget M et al. Radiol Oncol. 2016 May 12;50(4):402-408. eCollection 2016. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma – a phase II…

Details